DeutschNewstral
Article
Mmarketwatch.com on 2019-12-20 19:42
Stealth BioTherapeutics' stock falls on trial failure
Related news
- BAtara Biotherapeutics Stock Falls After Goldman Downgradebarrons.com
- PAtara Biotherapeutics stock falls on details of secondary stock offeringpacbiztimes.com
Concert stock falls 36 percent on Alzheimer's drug trial failurebizjournals.com- PAtara Biotherapeutics stock falls sharply after reporting big losspacbiztimes.com
- MBiogen stock declines after stroke trial failuremarketwatch.com
- PAtara Biotherapeutics announces $150 million stock offeringpacbiztimes.com
- BBoeing Stock Falls on 777 Engine Failure. That's Wrong.barrons.com
- Failure in late clinical trial pummels Proteon Therapeutics stockbizjournals.com
- MUltragenyx stock halted on late-stage trial failuremarketwatch.com
- Trial failure trips up Peninsula drug company's plans, halves stockbizjournals.com
- MMedtronic stock falls 0.5% after disappointing angioplasty trial datamarketwatch.com
Iovance Biotherapeutics Stock: Bull Market Is in Developmentprofitconfidential.com- MAbbVie's stock falls after lymphoma treatment trial data disappointsmarketwatch.com
- Penn spinout Vittoria Biotherapeutics emerges from stealth mode with $10M seed roundbizjournals.com
- PAtara Biotherapeutics raising $150 million in public stock offeringpacbiztimes.com
- MGTx Inc. stock drops 94% premarket after phase 2 trial failuremarketwatch.com
- MAbbVie stock down 1.8% in premarket trade after failure of glioblastoma drug trialmarketwatch.com
- MIdera Pharmaceuticals' stock plummets after phase 2 trial failure of dermatomyositis treatmentmarketwatch.com
- MPTC Therapeutics stock spikes on $200 million acquisition of Agilis Biotherapeuticsmarketwatch.com
- UniQure stock falls after news of new CFO, acquisition, and new trial databizjournals.com